Adimab Announces New Partnerships with Jounce, Five Prime, and Alector
Adimab, LLC, a leader in the discovery of monoclonal and bispecific antibodies, today announced collaborations with Jounce, Inc., Five Prime Therapeutics, Inc., and Alector, LLC. All three collaborations are structured as funded discovery deals whereby each partner may provide multiple targets to Adimab for the discovery and optimization of therapeutic monoclonal or bispecific antibodies.
“Adimab is focused on partnering with the best drug developers in the world, whether they are major pharmaceutical companies or smaller biotech companies,” said Tillman Gerngross, Co-Founder and Chief Executive Officer of Adimab. “We try to be flexible in structuring partnerships to ensure that we can work with the smartest and most experienced teams that are well positioned to take advantage of Adimab’s unique capabilities. Jounce, Five Prime, and Alector are good examples of that.”
This enthusiasm is echoed by Adimab’s newest partners.
“We view Adimab as a leader in the field in antibody discovery and having access to their technology will enhance Jounce’s ability to rapidly advance the discovery and development of novel therapeutics,” said Cary Pfeffer, Interim Chief Executive Officer of Jounce. “Adimab’s flexibility in structuring the transaction allowed us to take advantage of their world-class technology under terms that work well for a company of our size.”
“Five Prime is using its proprietary platform to discover proteins that potentially regulate the immune system and these molecules can be targets for therapeutic antibodies,” said Lewis T. “Rusty” Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime. “Adimab’s technology platform provides a rapid and effective means to generate therapeutic antibodies, allowing us to accelerate our research and development.”
“Adimab has demonstrated that its antibody discovery and optimization platform has significant advantages over alternative approaches,” said Arnon Rosenthal, Co-Founder, CEO and President of Alector. “We are thrilled to be leveraging the speed and flexibility of the Adimab platform against our targets and were excited to find terms that work for a company of our size.”
Under the terms of each of these three agreements, Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies or bispecifics for its customers. These agreements generally grant Adimab’s partners the right to develop and commercialize antibodies and, in some instances, bispecifics generated during the collaboration for potential use as therapeutic products. Adimab’s partners will typically fund research at Adimab and have the option to exclusively license antibodies and bispecifics generated during the collaboration. While the terms of individual agreements may vary, if a partner exercises its option for a particular target, Adimab would usually receive license fees, clinical milestones and royalties on therapeutic product sales.
Over the past four years, Adimab has established numerous partnerships with leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Human Genome Sciences, Gilead, Kyowa Hakka Kirin, GSK, and Celgene. Adimab’s partnerships range from single-target funded discovery projects to larger, multi-target funded discovery collaborations. In 2013, Adimab rolled out its technology transfer program, which allows pharmaceutical companies to obtain Adimab’s antibody discovery platform and custom antibody libraries for internal use at the Partner’s research site. Early adopters of Adimab’s technology transfer program include GSK, Biogen Idec, and Novo Nordisk. These collaborations focus on antibody discovery, optimization, humanization, and bispecifics for therapeutic products.